Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Return on Capital Employed (2020 - 2025)

Historic Return on Capital Employed for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to 1.55%.

  • Insight Molecular Diagnostics' Return on Capital Employed fell 8600.0% to 1.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.55%, marking a year-over-year decrease of 8600.0%. This contributed to the annual value of 1.28% for FY2024, which is 9700.0% down from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Return on Capital Employed stood at 1.55% for Q3 2025, which was down 8600.0% from 1.31% recorded in Q2 2025.
  • Insight Molecular Diagnostics' Return on Capital Employed's 5-year high stood at 0.21% during Q4 2022, with a 5-year trough of 1.55% in Q3 2025.
  • In the last 5 years, Insight Molecular Diagnostics' Return on Capital Employed had a median value of 0.52% in 2022 and averaged 0.69%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first skyrocketed by 2800bps in 2022, then tumbled by -9900bps in 2024.
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' Return on Capital Employed stood at 0.5% in 2021, then skyrocketed by 57bps to 0.21% in 2022, then crashed by -66bps to 0.35% in 2023, then plummeted by -280bps to 1.35% in 2024, then decreased by -15bps to 1.55% in 2025.
  • Its Return on Capital Employed was 1.55% in Q3 2025, compared to 1.31% in Q2 2025 and 1.54% in Q1 2025.